PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P

Cancer Letters

Volumn 376, Issue 1, 2016, Pages 148-154

  Huang, Bin ^a   Fu, Shun Jun ^a   Fan, Wen Zhe ^a   Wang, Zhong Hua ^b   Chen, Ze Bin ^a   Guo, Sheng Jie ^c   Chen, Jun Xing ^a   Qiu, Shao Peng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ABCB1; Cancer stem cell; Protein kinase C epsilon; Renal cell carcinoma; Side population cells

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; STAT3 PROTEIN; ABCB1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; PRKCE PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL ISOLATION; CELL PROLIFERATION; CELL SELECTION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RCC 769P CELL LINE; RENAL CELL CARCINOMA CELL LINE; SIDE POPULATION CELL; SIGNAL TRANSDUCTION; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, RENAL CELL; CELL SEPARATION; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; KIDNEY NEOPLASMS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; RNA INTERFERENCE; SCID MOUSE; TIME FACTOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; KIDNEY NEOPLASMS; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; P-GLYCOPROTEINS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE C-EPSILON; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIDE-POPULATION CELLS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSFECTION;

EID: 84962232304     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.03.041     Document Type: Article

References (38)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J. Clin 2015, 65:5-29.
2. Koul H., Huh J.S., Rove K.O., Crompton L., Koul S., Meacham R.B., et al. Molecular aspects of renal cell carcinoma: a review. Am. J. Cancer Res 2011, 1:240-254.
3. Kaiser J. The cancer stem cell gamble. Science 2015, 347:226-229.
4. Antoniou A., Hebrant A., Dom G., Dumont J.E., Maenhaut C. Cancer stem cells, a fuzzy evolving concept: a cell population or a cell property?. Cell Cycle 2013, 12:3743-3748.
5. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 2013, 12:133-143.
6. Fulawka L., Donizy P., Halon A. Cancer stem cells - the current status of an old concept: literature review and clinical approaches. Biol. Res 2014, 47:66.
7. Khan M.I., Czarnecka A.M., Helbrecht I., Bartnik E., Lian F., Szczylik C. Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. Stem Cell Res. Ther 2015, 6:178.
8. Golebiewska A., Brons N.H., Bjerkvig R., Niclou S.P. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011, 8:136-147.
9. Wu C., Alman B.A. Side population cells in human cancers. Cancer Lett 2008, 268:1-9.
10. Broadley K.W., Hunn M.K., Farrand K.J., Price K.M., Grasso C., Miller R.J., et al. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells 2011, 29:452-461.
11. Oates J.E., Grey B.R., Addla S.K., Samuel J.D., Hart C.A., Ramani V.A., et al. Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev 2009, 18:1515-1522.
12. Huang B., Huang Y.J., Yao Z.J., Chen X., Guo S.J., Mao X.P., et al. Cancer stem cell like side population cells in clear cell renal cell carcinoma cell line 769P. PLoS ONE 2013, 8:e68293.
13. Beverly A.T. Protein kinase C as a therapeutic target. Clin. Cancer Res 2006, 12:5336-5345.
14. Jain K., Basu A. The multifunctional protein kinase C-ε in cancer development and progression. Cancer 2014, 6:860-878.
15. Steinberg S.F. Structural basis of protein kinase C isoform function. Physiol. Rev 2008, 88:1341-1378.
16. Batarseh A., Li J., Papadopoulos V. Protein kinase C epsilon regulation of translocator protein (18 kDa) Tspo gene expression is mediated through a MAPK pathway targeting STAT3 and c-Jun transcription factors. Biochemistry 2010, 49:4766-4778.
17. Mohammed A., Janakiram N.B., Brewer M., Ritchie R.L., Marya A., Lightfoot S., et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl. Oncol 2013, 6:649-659.
18. Gorin M.A., Pan Q. Protein kinase Cε: an oncogene and emerging tumor biomarker. Mol. Cancer 2009, 8:9.
19. Sunayama J., Matsuda K.I., Sato A., Tachibana K., Suzuki K., Narita Y., et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010, 28:1930-1939.
20. Huang B., Cao K.Y., Li X.B., Guo S.J., Mao X.P., Wang Z., et al. The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma. J. Exp. Clin. Cancer Res 2011, 30:88.
21. Beck B., Blanpain C. Unravelling cancer stem cell potential. Nat. Rev. Cancer 2013, 13:727-738.
22. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med 1996, 183:1797-1806.
23. Wang M., Wang Y., Zhong J. Side population cells and drug resistance in breast cancer. Mol. Med. Rep 2015, 11:4297-4302.
24. He K., Xu T., Xu Y., Ring A., Kahn M., Goldkorn A. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. Int. J. Cancer 2014, 134:43-54.
25. Xia P., Xu X.Y. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am. J. Cancer Res 2015, 5:1602-1609.
26. Gobbi G., Di Marcantonio D., Micheloni C., Carubbi C., Galli D., Vaccarezza M., et al. TRAIL up-regulation must be accompanied by a reciprocal PKC epsilon down-regulation during differentiation of colonic epithelial cell: implications for colorectal cancer cell differentiation. J. Cell. Physiol 2012, 227:630-638.
27. Singh A., Sand J.M., Heninger E., Hafeez B.B., Verma A.K. Protein kinase C epsilon, which is linked to ultraviolet radiation-induced development of squamous cell carcinomas, stimulates rapid turnover of adult hair follicle stem cells. J. Skin Cancer 2013, 2013:452425.
28. Huang J., Guo J., Beigi F., Hodgkinson C.P., Facundo H.T., Zhang Z., et al. HASF is a stem cell paracrine factor that activates PKC epsilon mediated cytoprotection. J. Mol. Cell. Cardiol 2014, 66:157-164.
29. Bourguignon L.Y., Spevak C.C., Wong G., Xia W., Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem 2009, 284:26533-26546.
30. Addla S.K., Brown M.D., Hart C.A., Ramani V.A., Clarke N.W. Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. Am. J. Physiol. Renal Physiol 2008, 295:F680-F687.
31. Cojoc M., Mäbert K., Muders M.H., Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin. Cancer Biol 2015, 31:16-27.
32. Richard V., Sebastian P., Nair M.G., Nair S.N., Malieckal T.T., Santhosh Kumar T.R., et al. Multiple drug resistant, tumorigenic stem-like cells in oral cancer. Cancer Lett 2013, 38:300-316.
33. Hawley T.S., Riz I., Yang W., Wakabayashi Y., Depalma L., Chang Y.T., et al. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am. J. Hematol 2013, 88:265-272.
34. Porta C., Paglino C., Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front. Oncol 2014, 4:64.
35. Chang L., Graham P.H., Hao J., Ni J., Bucci J., Cozzi P.J., et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 2013, 4:e875.
36. Vondriska T.M., Klein J.B., Ping P. Use of functional proteomics to investigate PKC epsilon-mediated cardioprotection: the signaling module hypothesis. Am. J. Physiol. Heart Circ. Physiol 2001, 280:H1434-H1441.
37. Benavides F., Blando J., Perez C.J., Garg R., Conti C.J., DiGiovanni J., et al. Transgenic overexpression of PKC epsilon in the mouse prostate induces preneoplastic lesions. Cell Cycle 2011, 10:268-277.
38. Sand J.M., Aziz M.H., Dreckschmidt N.E., Havighurst T.C., Kim K., Oberley T.D., et al. PKC epsilon overexpression, irrespective of genetic background, sensitizes skin to UVR-induced development of squamous-cell carcinomas. J. Invest. Dermatol 2010, 130:270-277.